Actuate Therapeutics ACTU 深 沪
等待开盘 12-13 09:30:00 美东时间
7.52
+0.100
+1.35%
华盛通- 最 高7.64
- 今 开7.46
- 成交量 10.47万股
- 最 低 7.30
- 昨 收 7.42
- 总市值 1.72亿
- 52周最高 11.99
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 5.47
- 委 比 39.94%
- 总股本 2292.19万
- 历史最高 11.99
- 量 比 1.03
- 振 幅 4.58%
- 历史最低 5.47
- 每 手 1
- 风险率 1.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Actuate Therapeutics Signs $100M Sales Agreement
An update from Actuate Therapeutics, Inc. ( ($ACTU) ) is now available. On Nove...
11-29 06:48
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $20 price target.
11-19 19:32
Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate
Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.07 percent. This is a 54.55 percent increase over losses of $(0.55) per share
11-14 06:44
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Actuate Therapeutics Advances Elraglusib As Potential Backbone Therapy For Pancreatic Cancer With Phase 2 Data Supporting Upcoming FDA And EMA Submissions
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through
09-22 20:47
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Actuate Therapeutics announced positive findings for elraglusib, a GSK-3β inhibitor, showing improved survival in metastatic pancreatic cancer when combined with gemcitabine/nab-paclitaxel (GnP). The Phase 2 trial demonstrated a statistically significant increase in median overall survival, with a 37% reduction in death risk and doubled 12-month survival rate. The company secured $17.25 million to advance regulatory submissions and further studie...
09-22 12:45
Actuate Therapeutics Prices $15M Public Offering Of 2,142,858 Shares At A Price Of $7.00/Share
Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the
09-10 20:39
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 7.7% to $2...
09-10 05:06
Actuate Therapeutics shares are trading lower after the company announced an underwritten public offering.
Actuate Therapeutics shares are trading lower after the company announced an un...
09-10 04:24
